Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2011

View Archived Issues

Alzheimer's Drug Discovery Foundation awards drug development grant to Madera Biosciences

New biomarker described of mortality and hospitalization due to chronic heart failure

Findings from phase IV ESSENCE-DIABETES study disclosed

New neuraminidase inhibitors presented by Canadian university

Novel antibacterial agents synthesized by KBP Biosciences

Nerviano Medical Sciences discloses new B-raf inhibitors

NicOx reports novel agents for neuropathic pain

Boehringer Ingelheim presents novel HCV NS5A inhibitors

New corticotropin-releasing factor CRF1 receptor antagonists claimed

Bivalent HPV-16/18 vaccine shows potential against anal HPV infection

Study identifies new SNPs linked to risk of prostate cancer-specific mortality

Extended-release tapentadol receives FDA approval for chronic pain

Boehringer Ingelheim to launch new phase II trial of dabigatran etexilate

Abbott and Eisai to launch pancreatic digestive enzyme replacement products in Japan

Astellas Pharma applies for approvals of mirabegron in U.S. and Europe

Afexa Life Sciences reports encouraging results from pediatric clinical trial of COLD-FX

Phase III trial compares Ferinject and Venofer in IBD-associated iron deficiency anemia

Actelion reports results from MUSIC trial of macitentan

Takeda initiates two phase II trials of TAK-385 in Japan

Mologen reports results from phase I/II renal cancer trial

PAION initiates phase Ib study of Solulin

Novartis receives complete response letter from FDA regarding canakinumab

Cellestis acquired by QIAGEN

Berinert for self-administration approved in Europe

FDA approves Xalkori and companion diagnostic kit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...